57,127 Shares in Grail, Inc. (NASDAQ:GRAL) Bought by Squarepoint Ops LLC

Squarepoint Ops LLC bought a new stake in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 57,127 shares of the company's stock, valued at approximately $1,020,000. Squarepoint Ops LLC owned about 0.17% of Grail as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. State of Tennessee Department of Treasury purchased a new position in Grail during the 4th quarter worth $28,000. Lindbrook Capital LLC bought a new stake in Grail in the 4th quarter worth about $28,000. Sterling Capital Management LLC purchased a new stake in Grail in the 4th quarter valued at about $29,000. Wellington Shields Capital Management LLC bought a new position in shares of Grail during the 4th quarter worth approximately $33,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Grail during the 4th quarter worth approximately $41,000.

Grail Stock Performance

GRAL traded up $1.46 during midday trading on Wednesday, reaching $40.01. The company had a trading volume of 1,135,757 shares, compared to its average volume of 1,258,175. Grail, Inc. has a 12-month low of $12.33 and a 12-month high of $63.99. The business has a 50-day moving average price of $32.70 and a two-hundred day moving average price of $28.80. The stock has a market cap of $1.44 billion and a PE ratio of -0.66.

Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($3.10) EPS for the quarter, beating the consensus estimate of ($4.03) by $0.93. The business had revenue of $31.84 million for the quarter, compared to analysts' expectations of $35.80 million. On average, research analysts anticipate that Grail, Inc. will post -15.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on GRAL shares. Morgan Stanley increased their price target on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 18th. Canaccord Genuity Group upped their price objective on Grail from $32.00 to $43.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th.

Insiders Place Their Bets

In other Grail news, CFO Aaron Freidin sold 1,816 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $56,659.20. Following the transaction, the chief financial officer now directly owns 335,170 shares in the company, valued at $10,457,304. This trade represents a 0.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Joshua J. Ofman sold 2,109 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $65,800.80. Following the transaction, the president now directly owns 559,673 shares in the company, valued at approximately $17,461,797.60. This represents a 0.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 194,948 shares of company stock worth $6,583,130 in the last ninety days. 1.85% of the stock is currently owned by insiders.

Grail Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.